Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

• Published in: Journal of the American College of Cardiology Vol. 61; no. 7; pp. 723 - 727
• Main Authors: Wittfeldt, Ann, Emanuelsson, Håkan, Brandrup-Wognsen, Gunnar, van Giezen, J.J.J., Jonasson, Jenny, Nylander, Sven, Gan, Li-Ming
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 19.02.2013; Elsevier; Elsevier Limited
• Subjects: Acute coronary syndromes; acute myocardial-infarction; adenosine; Adenosine - analogs & derivatives; Adenosine - pharmacology; adjunct; Adolescent; Adult; Biological and medical sciences; Blood Flow Velocity - drug effects; Blood Flow Velocity - physiology; Cardiology; Cardiology and Cardiovascular Disease; Cardiology. Vascular system; Cardiovascular; clopidogrel; Confidence intervals; coronary blood flow; Coronary heart disease; Coronary Vessels - drug effects; Coronary Vessels - physiology; Cross-Over Studies; Double-Blind Method; Drug Synergism; Drug therapy; dyspnea; Flow velocity; Heart; Heart attacks; Humans; Kardiologi och kardiovaskulära sjukdomar; Male; Medical sciences; multicenter; Physiology; Purinergic P2Y Receptor Antagonists - pharmacology; ticagrelor; trial; Up-Regulation - drug effects; Up-Regulation - physiology; Variance analysis; Vasodilation - drug effects; Vasodilation - physiology; Young Adult; Sweden; adenosine; CBFV; CV; CI; dyspnea; ticagrelor; coronary blood flow; LAD; AUC; left anterior descending coronary artery; area under the curve; confidence interval; coronary blood flow velocity; coefficient of variation; Human; Purine nucleoside; Adenosine; Coronary artery; Cardiovascular disease; Coronary heart disease; Antiplatelet agent; Vasodilation; Response; Vasomotricity; Circulatory system; Cardiology; Ticagrelor

This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects. Ticagrelor is a P2Y12 receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and...